Ticagrelor (Brilinta; AstraZeneca) doesn’t lessen risks of MI or death and may increase bleeding relative to clopidogrel, according to the results of a study in a real-world ACS population. Across ...

Ticagrelor may not have an advantage over clopidogrel as part of a dual antiplatelet therapy (DAPT) regimen when it comes to treating ACS patients who have undergone PCI in everyday practice, a large ...

ORLANDO, Fla.—AstraZeneca may have just found a new niche for blood thinner Brilinta. Sunday at the American College of Cardiology's 67th Annual Scientific Session, the British pharma giant presented ...

HealthDay News — Ticagrelor is not superior to clopidogrel for reduction of cardiovascular events in patients with peripheral artery disease, according to a study published online November 13 in the ...

ORLANDO, Fla., Nov 15 (Reuters) - Heart attack patients in need of emergency procedures were less likely to suffer further serious cardiovascular events, including death, when given AstraZeneca's ...

New data from a late-stage, head-to-head trial demonstrates that a group of the sickest heart attack patients taking AstraZeneca's experimental blood clot drug Brilinta experienced fewer serious ...

(HealthDay News) — Autologous platelet transfusion 24 or 48 hours after ticagrelor-mediated platelet inhibition has minimal effect, while a small reversing effect is seen for transfusion after ...

Top-line results of the EUCLID trial did not demonstrate a benefit of ticagrelor over clopidogrel for prevention of atherothrombotic events in patients with symptomatic peripheral artery disease, ...

BARCELONA (Reuters) - AstraZeneca's new pill Brilinta for preventing heart attacks works better than Plavix, the world's second biggest selling drug, without increasing the amount of life-threatening ...

Among people younger than 75 years who were given clot busters to treat a heart attack, taking the more potent blood thinner ticagrelor did not increase the risk of major bleeding (the primary ...